Published in Crit Care on May 01, 2015
Protective Role of Kallistatin in Vascular and Organ Injury. Hypertension (2016) 0.77
Prognostic value of natriuretic peptides in severe trauma patients with multiple organ dysfunction syndrome. Exp Ther Med (2015) 0.75
Genetic variants in SERPINA4 and SERPINA5, but not BCL2 and SIK3 are associated with acute kidney injury in critically ill patients with septic shock. Crit Care (2017) 0.75
Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury. FEBS J (2017) 0.75
Kallistatin suppresses cancer development by multi-factorial actions. Crit Rev Oncol Hematol (2017) 0.75
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med (2001) 46.58
Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem (1979) 41.65
The immunopathogenesis of sepsis. Nature (2002) 11.83
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A (2003) 7.14
SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol (2007) 6.89
Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med (2013) 6.04
Sepsis definitions: time for change. Lancet (2013) 5.63
Novel strategies for the treatment of sepsis. Nat Med (2003) 5.14
Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis (2000) 3.03
Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun (1999) 2.13
Targeting HMGB1 in inflammation. Biochim Biophys Acta (2009) 2.11
Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci U S A (2009) 2.04
Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol (2003) 2.00
Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med (2001) 1.96
SOCS3 deficiency promotes M1 macrophage polarization and inflammation. J Immunol (2012) 1.71
BCL2 genetic variants are associated with acute kidney injury in septic shock*. Crit Care Med (2012) 1.61
Molecular mechanism of lipopolysaccharide-induced SOCS-3 gene expression in macrophages and microglia. J Immunol (2007) 1.58
Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood (2002) 1.54
Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med (1996) 1.48
Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem (1992) 1.34
Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum (2005) 1.31
Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension (2008) 1.28
Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol (2003) 1.20
Negative regulation of cytokine and TLR signalings by SOCS and others. Adv Immunol (2005) 1.19
Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension (2010) 1.12
Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol (2010) 1.11
Kruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression. J Biol Chem (2009) 1.09
Identification of a major heparin-binding site in kallistatin. J Biol Chem (2001) 1.08
Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci (1997) 1.07
Biochemistry, regulation and potential function of kallistatin. Biol Chem Hoppe Seyler (1995) 0.95
Genipin attenuates sepsis by inhibiting Toll-like receptor signaling. Mol Med (2012) 0.93
Year in review 2010: Critical Care--Multiple organ dysfunction and sepsis. Crit Care (2011) 0.91
A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein. J Biol Chem (2000) 0.90
SOCS3 expression induced by PIM2 requires PKC and PI3K signaling. Mol Immunol (2009) 0.90
Gene delivery of SOCS3 protects mice from lethal endotoxic shock. Cell Mol Immunol (2005) 0.89
Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection. Antimicrob Agents Chemother (2013) 0.88
Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. Biochim Biophys Acta (2000) 0.88
The PPE18 protein of Mycobacterium tuberculosis inhibits NF-κB/rel-mediated proinflammatory cytokine production by upregulating and phosphorylating suppressor of cytokine signaling 3 protein. J Immunol (2011) 0.86
Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology (2014) 0.86
Targeting myeloid differentiation 2 for treatment of sepsis. Front Biosci (Landmark Ed) (2014) 0.85
Kallikrein-binding protein inhibits LPS-induced TNF-α by upregulating SOCS3 expression. J Cell Biochem (2013) 0.80